← boardnext 2026-11
DBVT
DBV Technologiesdistress 4/10 · elevated risk$13.24-3%today-46% from 52w high
Lead: peanut allergy in toddlers 1-3 years old
Revenue
pre-revenue
Liquidity
$175M
Runway
1.0 yrs
Shares 1y
+116%
Price & events
-42.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-10.9%
1W
-17.8%
1M
-31.6%
3M
-46.1%
6M
+39.8%
1Y
+1252.1%
2Y
+23.5%
5Y
+140.7%
All
Overview
- Market Cap
- $3.92B
- Volume
- 17.34K
- 52 Week Range
- $8.51 – $24.54
- Total Shares
- 296.06M
- Float Shares
- 35.25M
- Short %
- 2.20%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 37.25%
- RVOL
- 0.06x
- Beta
- -0.21
Pipeline stages · 1 programs
DBV712 250 mcg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2027-01-15 | Phase 3 | DBV712 250 mcg | Allergy, Peanut Allergy | — | recruiting |
Catalyst news & presentations · 8
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)Viaskin peanut patch · BLA submission for 1-3 year old indication, subject to COMFORT Toddlers studySEC 8-K
- 2026-07-29earningsEarningsEarnings releaseyahoo
- first half of 2026regulatory submissionFiled (NDA/BLA)Viaskin peanut patch · BLA submission for Viaskin peanut patchSEC 8-K
- fourth quarter of 2025readoutPhase 3Viaskin peanut patch · Topline results from VITESSE Phase 3 studySEC 8-K
- second quarter of 2025trial initiationsecondaryPhase 3Viaskin Peanut · COMFORT Toddlers study to initiate, double-blind placebo-controlled, ~480 subjects.SEC 8-K
- 2025-03-24fda agreementViaskin peanut patch · FDA agreed that safety exposure data from VITESSE Phase 3 and OLE are sufficient for BLA; COMFORT Children study no longer required.SEC 8-K
- January 9-12, 2025conferencedata presentationsecondaryVIASKIN Peanut · Poster presentations at Eastern Food Allergy & Comorbidity ConferenceSEC 8-K
- 2024-12-11fda agreementViaskin Peanut · FDA confirmed Accelerated Approval pathway for toddlers 1-3 years, agreed EPITOPE data as intermediate endpoint and post-marketing study design.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 296,061,497 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $41 (+207% upside) · 6 analysts
- 2026-06-30CitizensMarket Outperform
- 2026-05-04GuggenheimBuy
- 2026-05-01CitizensMarket Outperform
- 2026-03-27CitizensMarket Outperform
- 2026-03-27GuggenheimBuy
- 2025-12-17Cantor FitzgeraldOverweight
Competitors — peanut allergy in toddlers 1-3 years old
- none identified
Recent news
- 2026-07-20DBVT Q2 2026 Earnings: Wider-Than-Expected Loss Triggers Negative Market Reaction - Earnings Turnaround - dars.gov.et
- 2026-07-18Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT), Intuitive Surgical (ISRG) and Staar Surgical (STAA) - The Globe and Mail
- 2026-07-17DBVT Secures $150M Shelf Registration to Support Future Growth - GuruFocus
- 2026-07-17DBV Technologies dépose un prospectus relatif à son - GlobeNewswire
- 2026-07-17DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - GlobeNewswire
- 2026-07-17DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales - GlobeNewswire
- 2026-07-17LifeSci Capital Maintains DBV Technologies(DBVT.US) With Buy Rating, Cuts Target Price to $45 - Moomoo
- 2026-07-17DBVT: Progress Towards Commercial Readiness by 2026 - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.